The global next generation sequencing (NGS) market is expected to register a robust CAGR of around 15% over the next five years. This growth is primarily driven by the rising adoption of precision ...

NeoGenomics’ third quarter results were met with a negative market reaction, as shares declined following the announcement. Management attributed the quarter’s performance to robust growth in clinical ...

Whole genome analysis plays a critical role in the development of life-saving diagnostics, therapeutics, and vaccines, with growing interest in noncoding regions and Whole genome analysis plays a ...

Giovanna Prout joins Countable Labs as CEO to accelerate commercialization of Countable Labs’ products Countable Labs, the developer of Countable PCR, a category-defining PCR technology that sets a ...

Bulk harvest release testing for adventitious viruses is an integral part of biosafety for manufacturing biopharma products. Finding a testing strategy that works for diverse biologics modalities ...

The webinar series titled "The Basics of Next Generation Sequencing and its Application in Precision Oncology" aims to provide a comprehensive understanding of the fundamentals and practical ...

Q3 2025 Management View CEO Anthony Zook highlighted record clinical volumes and revenues for the third quarter of 2025, emphasizing the company’s progress in next-generation sequencing (NGS) and ...

NeoGenomics Inc. ( ($NEO) ) has released its Q3 earnings. Here is a breakdown of the information NeoGenomics Inc. presented to its investors.

Caris Life Sciences® (NASDAQ: CAI), a leading, patient-centric, next-generation AI TechBio company and precision medicine ...